1.79
-0.01(-0.56%)
Currency In USD
Address
830 Winter Street
Waltham, MA 02451
United States of America
Phone
857 399 9500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
194
First IPO Date
July 16, 2021
| Name | Title | Pay | Year Born |
| Dr. Gavin MacBeath Ph.D. | Chief Executive Officer & Director | 1.03M | 1971 |
| Dr. Chrystal U. Louis M.D., M.P.H. | Chief Medical Officer | 550,125 | 1977 |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal & Strategy Officer and Company Secretary | 657,200 | 1971 |
| Mr. Jim Murray | Senior Vice President & Head of Development Operations | 0 | N/A |
| Ms. Ann Hargraves | Senior Vice President of Human Resources | 0 | N/A |
| Dr. Justin McCue Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. Shrikanta Chattopadhyay M.D. | Senior Vice President & Head of Translational Medicine | 0 | N/A |
| Mr. Ray Lockard M.B.A. | Senior Vice President & Head of Quality | 0 | N/A |
| Mr. Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board | 0 | N/A |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.